Fig. 3From: Major adverse cardiovascular events with basal insulin peglispro versus comparator insulins in patients with type 1 or type 2 diabetes: a meta-analysisHazard Ratios for MACE+ by subgroup. BIL basal insulin peglispro; DM diabetes mellitus; CVD cardiovascular diseaseBack to article page